Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Immunology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : VUMERITY (diroximel fumarate) is approved next-generation oral fumarate for treatment of adults with relapsing-remitting multiple sclerosis. Data from Phase 3 EVOLVE-MS-2 study demonstrated low discontinuation rates due to its gastrointestinal tolerabili...
Brand Name : Vumerity
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 17, 2021
Lead Product(s) : Diroximel fumarate
Therapeutic Area : Immunology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?